Zoetis Inc. $ZTS Stake Cut by Bokf Na

Bokf Na reduced its stake in Zoetis Inc. (NYSE:ZTS) by 35.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 24,011 shares of the company’s stock after selling 13,050 shares during the period. Bokf Na’s holdings in Zoetis were worth $1,677,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ZTS. Physician Wealth Advisors Inc. raised its holdings in shares of Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after acquiring an additional 91 shares during the period. Lipe & Dalton boosted its position in shares of Zoetis by 2.2% during the 1st quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock valued at $555,000 after acquiring an additional 102 shares during the last quarter. Root Financial Partners LLC grew its holdings in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Valmark Advisers Inc. grew its holdings in shares of Zoetis by 7.7% in the first quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock valued at $207,000 after purchasing an additional 125 shares during the period. Finally, Balefire LLC increased its position in Zoetis by 6.7% during the first quarter. Balefire LLC now owns 1,996 shares of the company’s stock worth $236,000 after purchasing an additional 125 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

ZTS stock opened at $79.67 on Friday. The business’s fifty day moving average price is $75.04 and its 200 day moving average price is $93.64. Zoetis Inc. has a 12-month low of $68.77 and a 12-month high of $144.83. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $32.92 billion, a PE ratio of 13.13, a P/E/G ratio of 1.18 and a beta of 0.74.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. During the same period last year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio is presently 34.93%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZTS. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research note on Tuesday, August 25th. Stifel Nicolaus decreased their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Jefferies Financial Group cut shares of Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the company from $103.00 to $83.00 in a research note on Tuesday, October 20th. UBS Group raised their price target on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Piper Sandler reduced their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. Six research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $93.79.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.